Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation in patients with non-cancer pain.
Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis receive the treatment as follows:
Patients will be randomly assigned to receive open label tegaserod 6 mg b.i.d. or tegaserod 12 mg o.d. using an allocation ratio of 1:1.
Patients who enter this study AFTER the core study interim analysis receive the treatment as follows:
Patients will be assigned to receive the selected tegaserod dose regimen (as determined by the core study interim analysis) in an open label fashion.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Egypt, Egypten
- 6 Investigative Sites
-
-
-
-
New Jersey
-
East Hanover, New Jersey, Forenede Stater
- 60 Investigative Sites
-
-
-
-
-
Hong Kong, Kina
- 2 Investigative Sites
-
-
-
-
-
Singapore, Singapore
- 1 Investigative Site
-
-
-
-
-
Taiwan, Taiwan
- 2 Investigative Sites
-
-
-
-
-
Venezuela, Venezuela
- 4 Investigative Sites
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male and female outpatients 18 years of age or older.
- Patients with chronic non-cancer pain that necessitates the use of non- injectable opioid analgesics.
- Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.
- Constipation, according to the investigator's clinical judgment, that is resulting from opioid use for non-cancer chronic pain. Opioid-induced Constipation (OIC) is defined as follows:
less than 3 spontaneous bowel movements per week and at least one of the following on at least 25% of occasions:
- Hard or very hard stools
- sensation of incomplete evacuation
- straining while having a bowel movement
Exclusion Criteria:
- 1. Who are receiving opioids for abdominal pain or connective tissue disorders.
- Planned discontinuation of opioids during the study
- Who underwent major surgery within 3 months prior to screening.
- With a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
- With a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.
- With a previous use of tegaserod within 3 months prior to baseline.
Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
|---|
|
To evaluate the long term safety of tegaserod
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
|---|
|
Change from baseline assessment of OIC symptoms at weeks 24 and 52
|
|
Change from baseline assessment of opioid-induced mid/upper GI symptoms at weeks 24 and 52
|
|
Patients weekly assessment of intensity of pain for which opioids were prescribed at weeks 24 and 52
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Novartis Pharmaceuticals Corp., NPC
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Kemisk inducerede lidelser
- Stof-relaterede lidelser
- Tegn og symptomer, fordøjelsessystemet
- Narkotika-relaterede lidelser
- Forstoppelse
- Opioid-induceret obstipation
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Serotoninmidler
- Serotoninreceptoragonister
- Tegaserod
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CHTF919N2302
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .